Your browser doesn't support javascript.
loading
GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species.
Rutter, A Richard; Poffe, Alessandro; Cavallini, Palmina; Davis, T Gregg; Schneck, Jessica; Negri, Michele; Vicentini, Elena; Montanari, Dino; Arban, Roberto; Gray, Frank A; Davies, Ceri H; Wren, Paul B.
Afiliação
  • Rutter AR; GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.
  • Poffe A; GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.
  • Cavallini P; GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.
  • Davis TG; GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.
  • Schneck J; GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.
  • Negri M; GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.
  • Vicentini E; GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.
  • Montanari D; GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.
  • Arban R; GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.
  • Gray FA; GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.
  • Davies CH; GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.
  • Wren PB; GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.
J Pharmacol Exp Ther ; 350(1): 153-63, 2014 Jul.
Article em En | MEDLINE | ID: mdl-24784567
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oxidiazóis / Tiazóis / Córtex Cerebral / Nootrópicos / Nucleotídeo Cíclico Fosfodiesterase do Tipo 4 / Inibidores da Fosfodiesterase 4 Idioma: En Revista: J Pharmacol Exp Ther Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oxidiazóis / Tiazóis / Córtex Cerebral / Nootrópicos / Nucleotídeo Cíclico Fosfodiesterase do Tipo 4 / Inibidores da Fosfodiesterase 4 Idioma: En Revista: J Pharmacol Exp Ther Ano de publicação: 2014 Tipo de documento: Article